Integra LifeSciences Holdings Corporation
NASDAQ•IART
CEO: Dr. Stuart M. Essig Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1995-08-16
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Contact Information
Market Cap
$1.05B
P/E (TTM)
-2.1
33
Dividend Yield
--
52W High
$27.13
52W Low
$10.87
52W Range
Rank50Top 56.1%
3.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$402.06M+5.57%
4-Quarter Trend
EPS
-$0.07-50.00%
4-Quarter Trend
FCF
$25.75M-459.59%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Modest Nine-month revenue reached $1.200B, showing low single-digit growth compared to $1.168B last year.
Goodwill Impairment Charge Recognized $511.4M goodwill impairment expense during Q2 2025, significantly impacting nine-month net loss.
Working Capital Position Improved Working capital increased to $779.5M as of September 30, 2025, driven by 2025 Notes repayment.
Acclarent Integration Progress Acclarent acquisition contributed to revenue growth, enhancing ENT specialty device market position post-closing.
Risk Factors
Significant Net Loss Recorded Nine-month net loss widened substantially to $(514.8)M versus $(26.4)M last year, driven by impairment.
Tariff Environment Uncertainty Evolving tariff changes create risks impacting cost of goods sold, demand, and general economic conditions.
Quality System Remediation Ongoing FDA warning letters regarding quality systems require remediation efforts impacting operations and approvals.
Operating Cash Flow Decline Operating cash flow decreased $40.1M for nine months, primarily due to lower net income and inventory increases.
Outlook
Braintree Facility Operationalization Anticipate PMA approval for SurgiMend in 2026 following completion and operationalization of Braintree facility.
Advancing Key Product Approvals Pursuing PMA approval for DuraSorb in 2026, continuing clinical trials for two-stage breast reconstruction.
Debt Covenant Management Leverage ratio covenant requirement drops to 4.75 to 1.00 starting Q4 2026, requiring continued compliance.
Focus on Core Growth Pillars Strategy centers on innovating for outcomes, growing internationally, and broadening impact across care pathways.
Peer Comparison
Revenue (TTM)
AHCO$2.85B
$1.64B
CNMD$1.35B
Gross Margin (Latest Quarter)
LFMD111.6%
INMD80.0%
ESTA70.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PRAX | $5.68B | -23.0 | -60.1% | 0.2% |
| ESTA | $2.11B | -25.9 | -253.8% | 0.9% |
| TNDM | $1.45B | -7.1 | -118.8% | 51.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 24, 2026
EPS:$0.80
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $402.06M+5.6%|EPS: $-0.07-50.0%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $415.61M-0.6%|EPS: $-6.33+3856.3%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 5, 2025|Revenue: $382.65M+3.7%|EPS: $-0.33+682.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 25, 2025|Revenue: $1.61B+4.5%|EPS: $-0.09-110.4%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 4, 2024|Revenue: $380.83M-0.4%|EPS: $-0.14-158.3%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 29, 2024|Revenue: $418.18M+9.7%|EPS: $-0.16-409.5%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 6, 2024|Revenue: $368.87M-3.1%|EPS: $-0.04-114.1%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 28, 2024|Revenue: $1.54B-1.0%|EPS: $0.87-60.1%Miss